F-1/A: NewGenIvf Group Limited Files Amendment No. 2 to Form F-1 Registration Statement for Share Resale

NewGenIvf Group Limited has filed an amendment to its Form F-1 registration statement, pertaining to the resale of up to 139,425,259 Class A Ordinary Shares by selling shareholders.

Summary

• NewGenIvf Group Limited, a British Virgin Islands holding company, has filed Amendment No. 2 to its Form F-1 registration statement.
• The filing concerns the resale of up to 139,425,259 Class A Ordinary Shares by the selling shareholders.
• These shares consist of (i) 86,704,087 Ordinary Shares issuable upon the conversion of senior convertible notes, (ii) 22,085,003 Ordinary Shares issuable upon the conversion of exchanged senior convertible notes, (iii) 19,871,935 Ordinary Shares that are issuable upon the exercise of Series A warrants, (iv) 180,722 Ordinary Shares that are issuable upon the exercise of Series B warrants, (v) 3,253,012 Ordinary Shares that are issuable upon the exercise of Series C warrants and (vi) 7,330,500 Ordinary Shares.
• The notes and warrants were issued in private placements to certain selling shareholders.
• NewGenIvf will not receive any proceeds from the sale of Ordinary Shares by the selling shareholders, but will receive proceeds from the exercise of the warrants if exercised for cash, which will be used for working capital and other general corporate purposes.
• The selling shareholders are offering their securities to further enhance liquidity in the public trading market for our equity securities in the United States.
• The Ordinary Shares currently trade on The Nasdaq Global Market under the symbol NIVF.
• As of September 4, 2024, there were 10,149,386 Ordinary Shares issued and outstanding.

Sentiment

Score: 4

Explanation: The document is largely factual, but the inclusion of Nasdaq deficiency letters and the lack of positive financial performance indicators temper the sentiment.

Positives

• The resale of shares by selling shareholders aims to enhance liquidity in the public trading market.
• The company will receive proceeds from the exercise of warrants if exercised for cash, which will be used for working capital and other general corporate purposes.

Negatives

• The company will not receive any proceeds from the sale of Ordinary Shares by the selling shareholders.

Risks

• Investing in the company's Ordinary Shares involves a high degree of risk, as detailed in the Risk Factors section of the prospectus.
• The company received a deficiency letter from Nasdaq for not meeting the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
• The company received a deficiency letter from Nasdaq for not meeting the minimum $50,000,000 Market Value of Listed Securities requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(A).
• The company received a deficiency letter from Nasdaq for not meeting the minimum $15,000,000 Market Value of Publicly Held Shares requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rules 5450(b)(2)(C).

Future Outlook

The selling shareholders may sell all or a portion of the Ordinary Shares from time to time in market transactions through any market on which our Ordinary Shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale.

Industry Context

The document highlights NewGenIvf's position as an assisted reproductive services (ARS) provider in the Asia-Pacific region, operating in a market driven by factors such as rising infertility rates, increasing social acceptance of ARS, and demographic trends like later maternal age. The company faces competition from other regional fertility service providers.

Stakeholder Impact

• Shareholders may experience dilution if warrants are exercised.
• The resale of shares by selling shareholders could impact the share price.

Next Steps

• The selling shareholders may proceed with the resale of the registered Ordinary Shares.
• The company intends to monitor the minimum bid price of its Class A Ordinary Shares and may, if appropriate, consider available options to regain compliance with the Nasdaq requirements.

Key Dates

Keywords

Ordinary Shares, Resale, Registration Statement, Warrants, Convertible Notes, Selling Shareholders, NewGenIvf, NIVF, Nasdaq